No Data
CICC: Maintains Hanyu-B (02256) "Outperform Industry" rating with a Target Price of HKD 6.76.
CICC maintains the forecast for the net income attributable to the parent company of Huayu-B (02256) at 2.13 million yuan and 27 million yuan for 2024 and 2025 respectively.
He Yu-B (02256.HK): The Phase II clinical study of the oral PD-L1 small molecule inhibitor ABSK043 combined with furmonertinib for the treatment of non-small cell lung cancer has completed the administration of the first patient.
On December 11, Gelonghui reported that Heyu-B (02256.HK) announced that the first patient has been treated in the "Phase II open-label clinical study assessing the efficacy and safety of ABSK043 in combination with Furmetinib in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations (Protocol No.: ABSK043-202)." ABSK043 is an oral small molecule PD-L1 inhibitor, developed independently by Heyu Pharmaceuticals, with good bioavailability, high selectivity, and high activity, and is currently being developed for the treatment of various malignant tumors. Furmetinib is from Shanghai Allist Pharmaceuticals Co., Ltd.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
Express News | 2024 Ash Oral Presentation----Abbisko Presents Promising Preliminary Phase 2 Study Results of Pimicotinib in the Treatment of Chronic Graft-Versus-Host Disease (Cgvhd) at the 66TH Ash Annual Meeting
At the ASH annual meeting, Heyu Pharmaceutical showcased positive preliminary Phase II study results of primustine in the treatment of cGvHD.
HeYue-B (02256) announced that its subsidiary, Shanghai HeYue Biomedical Technology Co., Ltd., presented the preliminary Phase II study results of Pimitinib (ABSK021) for patients with chronic graft-versus-host disease ("cGvHD") who had previously failed first-line or multiple lines of treatment, during an oral report at the 66th Annual Meeting of the American Society of Hematology ("ASH") held from December 7 to 10, 2024, in San Diego, California, USA. Although most of the enrolled patients have not yet completed the 6-month treatment cycle required for cGvHD response evaluation, among those who received Pimitinib...
Zhichun Hong Kong stocks early insights | The central bank has increased its gold shareholding for the first time in six months. Price wars in the winter car market of 2024 are cooling down.
On December 7, 2024, local time in the USA, the Senate and House Armed Services Committees of the USA Congress released the final agreement text of the 2025 National Defense Authorization Act (NDAA).
